Explore Beth Heredia's board "Cannabus Oil Saves Lives" on Pinterest. Vitamin Weed': Neuroscientist says cannabis oil slows down aging process .. A Users' Guide | Cannabis To Palliate Stress And Anxiety Brain The Folks At Senior Centers Are Using A Lot Of Marijuana — The . Jordan Hancock. I spoke with cannabis artist Marty Klein of Easthampton and medical marijuana Growing Your Own Weed In Massachusetts: A How-To Guide or whatever you call the bud bits and kief, for making cannabis butter or oil later. If you did your grow right, and have a lot of funky people in your life, your. Evolution of Essential Oil in Domesticated Cannabis Odor and Other .. Up to a century ago, most people lived on farms and were well acquainted . The term “inflorescence” refers to 1 2 Cannabis: A Complete Guide FIGURE as 11, BC in some places (Hancock ), is the foun- dation of civilization.
CBD Living Wisconsin Hancock, Hemp Oil Guide Folks In For
The Ancient Chinese used cannabis to treat constipation, malaria, rheumatic pain and female disorders. Consumption then spread to India and the Middle East, where Muslims used hashish.
The most commonly cited reason for this belief is that cannabis has never directly caused a death, while alcohol claims many lives each year.
In fact, according to the World Health Organization, there were 3. Of course, alcohol poisoning is responsible for some of these deaths. But the long-term effects of alcohol, such as chronic illnesses, cause the most deaths.
The use of medical marijuana has become more and more common in the U. Patients that are approved to use medical marijuana usually buy the drug from a licensed supplier. This could include anything from migraine headaches to a spinal injury. It can also be helpful for patients experiencing nausea and appetite loss, such as those undergoing chemotherapy. That may be tougher than you think. The bureau is updating that list of retailers almost daily.
Want to be there for the first fully legal sale? Share in the festivities: Leafly will continue to update this list as the BCC rolls out more pre-qualified licensees, right up through January 1. Some major cities and counties are allowing and licensing retail stores; others are banning all cannabis companies outright.
Our list of major cities starts below the table of pre-licensed retail stores. Local ordinances often determine opening dates and times. Oakland, for instance, allows 6am openings while in San Jose 9am is the earliest opening time. In West Hollywood, adult-use stores will open on Jan 2 due to local government rules. Our main piece of advice for those who want to enjoy the Opening Day excitement on Jan.
Check back with Leafly News on Jan. The first shops are expected to open shortly thereafter. Other adult-use stores are expected to be licensed and open around Jan. The seven stores cleared by the city and awaiting their state licenses are:. Look for the first openings by Jan or so. The city has approved four medical cannabis dispensaries within the city but is not yet allowing retail adult-use stores. But lawsuits have delayed implementation. Many retail stores are expected to be open on Jan.
Cathedral City may have the most licensed adult-use retail stores per capita in the entire state. The city prohibits all cannabis businesses, but is part of a county working group considering new regulations that may allow some form of cannabis commerce in the near future. Look for a proposed new ordinance sometime in Retail cannabis stores are banned in the unincorporated sections of the county. Orange County cities within: Retail stores banned in all OC counties except Santa Ana.
The city has zoned certain districts OK for cannabis retail. No pre-licensed retail businesses yet. The city will license two medical dispensaries but no adult-use retail stores. Since no single agency has an overarching responsibility, supporters and opponents of legalization worry how well the laws will be followed. Three state agencies will issue a combined 19 types of permits to growers, retailers, manufacturers, and distributors. Each agency has enforcement officers tasked with cracking down on unlicensed operators.
In addition, other state agencies such as Fish and Wildlife and the Narcotic Enforcement Bureau said they will rely on marijuana task forces already in place to continue eradicating illegal growers and sellers. The newly created state Bureau of Cannabis Control, which licenses retail outlets, said it has hired several officers to help crack down on unlicensed shops and plans to hire more in the coming months. But much of the work of arresting illegal operators will still fall to sheriffs and police departments.
He said about eight enforcement officers will be in place Jan. The bureau has issued fewer than temporary business licenses so far. While an increasing number of states have legalized marijuana in one form or another, all uses of the drug remain illegal under federal law.
Attorney General Jeff Sessions has said federal authorities still are contemplating how they will enforce cannabis laws in California.
Assemblyman Tom Lackey has introduced legislation that would make the California Highway Patrol the point agency for enforcing state marijuana laws, especially those seeking to stem the flow of cannabis out of state. Jerry Brown appointed her to run the cannabis bureau.
She said regulating marijuana is more complicated than policing alcohol because counties and cities have considerable authority over cannabis. State laws include that consumers be at least 21, that businesses not be within feet meters of schools and must close by 10 p.
Counties and cities have similar requirements with a few twists. Oakland city officials, citing disparate marijuana arrest records, have given applicants convicted of cannabis-related felonies preference in obtaining permits in certain neighborhoods.
Marijuana businesses also will be required to pay state taxes. Siskiyou County leaders recently declared a state of emergency and called on the governor to assist the sheriff with eradicating an influx of illegal farms.
Mendocino County Sheriff Tom Allman has similar concerns in a county that has legalized marijuana in the heart of the fabled cannabis growing region called the Emerald Triangle. The active ingredient, THC, is so much higher today than back 40 years ago. In some cases, the farmers are planting on government lands hidden deep in forests patrolled by state wildlife wardens. The agency also created Watershed Enforcement Teams to crack down on marijuana farmers who illegally divert streams, used banned pesticides or otherwise harm the environment.
Fish and Game Capt. Paul Foy said the department has no plans to change its enforcement strategy after Jan. An estimated 1, illegal farms controlled by organized crime operate on public property in California, he said. This magazine is dedicated to medical cannabis patients and providers nationwide, particularly those living in the 14 states and growing with laws protecting their rights.
It will provide insight into how canna businesspeople can use the law to their advantage. They are a community of advocates, patients, researchers and believers in the healing qualities of marijuana, with a commitment to bringing you stories from the patients themselves. We are an activist magazine dedicated to liberating marijuana.
News and tutorials about marijuana growing. Learn to grow marijuana at ILGM today by following this blog. Learn more about Colorado marijuana, including where to buy marijuana. Their goal is to keep our readers and clients informed with the latest news, current trends, and social commentary surrounding the recreational and medical marijuana industry.
Overnight and same-day delivery throughout all of California! The Medicinal Marijuana Association will give you the information you need to determine whether medicinal marijuana can help you achieve a better quality of life. Stay updated with the latest Marijuana news posts by Pot Valet.
Buy the most superior cannabis strains now! Cannabis Life Network is devoted to its mission of informing its readers of what matters in all things relating to cannabis and producing professional, entertaining, and educational content. Their goal is to make sure the patient knows where the closest dispensary, caregiver, attorney, or other business is based on their location. Best guides and pot tours.
Best selection pot friendly hotels. Arizona Medical Marijuana Certification Center provides certification for Medical Marijuana usage using a statewide accepted process.
Our medical marijuana doctors are highly qualified and have a deep understand of the health benefits of getting a medical cannabis card. Marijuana Mommy is dedicated to teaching MMJ facts and silencing propaganda. The most complete resource for ending your marijuana addiction and avoiding withdrawal. Bringing you the latest information, research, tips and tricks for quitting weed. PLPCC covers everything on medical cannabis.
Located in Wheat Ridge CO. We live to educate our customers on Seattle cannabis. Get updates on the latest products and developments in the cannabis industry. The Blunt Truth aims to be a go-to source for updates, reports and analysis on the changes in cannabis laws and regulations and how they impact your business.
Learn more about the marijuana industry. Stay up to date on the latest trends, rules and regulations regarding the industry and how to stay ahead. He has Colorado marijuana real estate for sale, and is an authority on owning a medical marijuana.. We have trained medical marijuana staff, on-site, ready to provide you with the safest medicinal options according to your diagnosis and symptoms. We are here to inform and educate South Africans on all things cannabis related.
Your Number one place to share your weed Pictures and Cannabis Grows. NM revolutionizes the way people talk and think about cannabis and medical marijuana. We know what investors should invest in in new growth industries such as The Cannabis Sector. Most Applications for the Medical Marijuana registry card are declined due to missing or incorrect documentation.
Our consultants will make sure your package contains all the needed information for the State of Michigan to grant you your registry card. Weed cannabis card, and cultivation licenses to the Californians.
Sale of marijuana seeds for self-cultivation, cabinets, fertilizers, head shop. Mission is to make available to anyone over 18 years of age all the information and products necessary for self-cultivation of cannabis, as well as promoting activism and responsible consumption of this millenary plant.
We cover the people plants products that fuel the unprecedented growth of this evolving industry. With market forces and business environments changing at a dynamic pace, we help industry leaders remain at the forefront of change by providing in-depth coverage of the topics.
And who understands that better than the very people who ask the questions all the time. After realizing there are still many unanswered questions about cannabis, we decided to get together and give our two cents to this constantly evolving market.
Stay up to date on all the trending issues and new cannabis technologies. Weed Depot is a marijuana industry resource, directory, and social platform where consumers and professionals can find information and locations for legal dispensaries, doctors, delivery services, etc. We share great content.
Our directory is a marijuana showcase. Evaluations from professional, licensed health practitioners. They are headquartered in the capital of Baton Rouge where we lobby at the local and state level, but have affiliates in every major city throughout Louisiana. Search questions already answered or in progress. We offer varities of strains such as brownies, hash THC, CBD,Cannabi oil, hemp oils, skunk for medical purposes such as biplomar, insomnia. We provide the best product reviews, beginner guides and advice to help you grow awesome buds!
I personally give you a high-five and want to thank you for your contribution to this world. If your blog is one of the Top 60 Marijuana blogs, you have the honor of displaying the following badge on your site. Use the below code to display this badge proudly on your blog.
Few, if any, industries are growing as quickly as legal marijuana. This rapid and consistent growth is exactly why investors have been drawn to marijuana stocks over the past couple of years. But at the heart of this rapid rise in sales is a discernible shift in the way consumers view marijuana.
Once seen as a dangerous drug, more and more Americans view marijuana to be less dangerous, in some instances, than alcohol. The case for legalization got even stronger this past week when national pollster Gallup released its annual survey that questioned random adults around the country about their views on pot.
Not surprisingly, the survey showed that support for legalizing marijuana hit an all-time record high for the second year in a row. While this in no way suggests that Capitol Hill is suddenly going to do an about-face on its cannabis policy, the idea is no longer as far-fetched as it might have seemed even one or two years ago.
This year and the next, pro-legalization groups have focused their efforts on Arizona, which lacked young adult turnout at the polls in younger adults typically have a more favorable view of pot. History has shown that the second time is often the charm when it comes to legalizing weed, with California, Oregon, and Florida all failing to pass a marijuana measure this decade, then easily succeeding on their second go-around.
Hopes are high in the Motor City as well, with Michigan angling to get a recreational cannabis measure on its ballot. Should you eventually need a heart transplant, you'll be in excellent hands. In , Cedars did the most adult heart transplants in the United States — and in the world. Their day postoperative mortality rate is under 2 percent.
Their one-year survival rate is a whopping 92 percent — well above the national average of 89 percent. Why is the program here so good? They have a good supply of hearts, for one. OneLegacy, their organ-procurement organization, has the most organs available for transplant, so waits are shorter. Also, the chance of rejection is much lower. Nationally, nearly a third of transplanted hearts are rejected by the host body.
Cedars' rejection rate is a mere 5 percent. Researchers here, it turns out, are pioneers in the realm of antirejection medications. Working with so many patients gives them a vast amount of data to draw from when trying to figure out what works and what doesn't. That, combined with a slew of talented doctors and nurses, is the best prescription for keeping the Grim Reaper's bony fingers off your ticker. Don't let the golden trumpeter throw you off; the best way to find your roots is by visiting the friendly folks of the Latter Day Saints.
An introduction to genealogical research plays on continuous PowerPoint loop behind the help desk. Tidy rows of patron computers offer free access to top commercial websites like Ancestry. Other resources include the well-organized microfilm libraries, not to mention the on-site book, map and records collections and additional LDS databases.
If it all seems a bit daunting, they offer three- and four-day genealogy intensive courses, and helpful volunteers, whose presence around the library is heralded by a small plastic flag. Your qi, your back and your wallet out of whack? In China, acupuncture has been used for thousands of years to alleviate everything from circulatory to digestive troubles, gynecological to neurological issues, pain both chronic and specific, and a double rainbow of other ailments. In the West, those barely-there needles are just as efficacious, but they require repeat and costly pokes most often on a cold, clinical table.
While completing her master's degree in Oriental medicine, Valerie Brown worked in China's Sichuan province, where patients are treated in a relaxed group setting. Luckily for Eastsiders living in pain but on a ramen budget, she brought the concept to Eagle Rock Community Acupuncture. A patient's first visit to Brown's clinic features a warm and extensive discussion of what ails them; sessions take place in a spacious room replete with soothing music, mood lighting and a collection of overstuffed recliners.
The comfy Zen not only seems to make the treatments more effective, the group setting allows the clinic to operate on a very non-Western sliding payment scale. The IPO helps put it on a path to join much larger companies developing cannabinoid-based drugs.
RepliCel's successful conclusion of its Phase 1 trial for hair loss sets it up for the next steps in the drug's development. Stellar Biotechnologies and Amaran Biotechnology have entered into an exclusive agreement where Stellar will supply KLH to the biopharmaceuticals manufacturer.
Several KLH-based vaccines are in trials for indications as varied as breast cancer and lupus, and clinical success could propel Stellar Biotechnologies, which is the only provider of KLH that has its own aquaculture facilities, says Jason McCarthy, an equity research analyst with Maxim Securities. Donald Trump's presidency is a real nitro boost for the future of the biotech sector in the U.
The stage has been set for high levels of uncertainly, and with uncertainty comes opportunities in commodities, posits Lior Gantz, editor of Wealth Research Group, who also sees opportunities in disruptive technologies in the medical arena. RXi Pharmaceuticals' proprietary self-delivering RNAi sd-rxRNA platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology.
It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. As Viveve Medical ramped up its U. Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration.
Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future. Veteran investor Bob Moriarty discusses Luminor Medical Technologies, whose Scout DS technology offers a noninvasive diabetic screen, measuring blood-sugar levels without taking blood.
The cannabis industry attained new highs in , paving the way for some big changes this year, says Tom Beck, senior editor of Portfolio Wealth Global.
Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers. Why should investors keep an eye on these twenty small-cap biotechs in ? Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases.
Now in its fifth year, the Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January.
The last several months have been active ones for Viveve: VistaGen Therapeutics has granted an exclusive sublicense for its stem cell technologies to BlueRock Therapeutics, a new biotech backed by pharma heavyweight Bayer AG and venture capital firm Versant Ventures of San Francisco.
Technical analyst Clive Maund charts movements in the cannabis sector after the Nov. Gecko Research discusses the bull market for marijuana, the road to legalization in Canada and why Emblem Corp. Reliq Health Technologies is initiating a trial of its remote patient monitoring system with The Feldman Institute in Louisiana, the fourth program for the company's innovative technology.
With the election now nearly a month old, and hot-button issues such as drug pricing still in the press, industry watchers have begun to weigh in on what might happen in the biotech and pharma markets when Trump takes office. By securing an exclusive option to acquire MirImmune Inc.
Due to drug pricing controversies, there has been much concern about how the outcome of the upcoming election will affect pharmaceutical stocks. Rising healthcare costs continue to preoccupy providers, patients, politicians and investors. Some cost increases stem from inefficiencies in the medical system, some from social and demographic trends, and others are a function of profit motives on the part of insurers and a few drug companies. Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group.
These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function.
Australian regenerative medicine company Regeneus Ltd. Bob Moriarty profiles Imagin Medical, a company that has developed a new way of detecting bladder cancer through endoscopes. The late-stage biopharmaceutical company Soligenix has had a string of good news. This, according to Maxim Group analyst Jason Kolbert, will help the company determine an "optimal" strategy for intradermal skin vaccination.
Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching. Concerned about investing in the life sciences in the United States, where markets have slumped in and the presidential election furthers volatility?
With its lead drug candidate apabetalone already in Phase 3 targeting major adverse cardiac events, Resverlogix has expanded its scope by initiating a Phase 1 study of the small molecule to further investigate its potential applications.
Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly, for the patients whose addictions have become debilitating or fatal. In tandem with the broader markets, the biotech indices reeled on the news of Britain's vote to exit the European Union. Given the uncertainty and dire economic forecasts, The Life Sciences Report has reviewed commentary from sector experts and biotech publications to help investors understand what Brexit might mean for the industry.
With blockbuster indications like cancer, lupus and Alzheimer's disease being targeted by partners, and a manufacturing process sure to satisfy regulators, McCarthy lays out a value proposition for Stellar's KLH that investors should not ignore. After decades of disappointment, cell therapies and gene therapies are finally seeing light at the end of the tunnel.
Investors, investigators, clinicians, and patients with serious unmet needs are watching pivotal trials move into the home stretch. Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies at the forefront of cancer treatment.
Managing both acquisitions and internal growth at the same time is difficult for most small companies, akin to drinking water and singing at the same time. Not so for Nobilis Health Corp. The conductor is merger-and-acquisition specialist Kolin Ozonian, who brings years of business development experience in large-cap healthcare to this small-cap enterprise.
In this interview with The Life Sciences Report , Ozonian discusses his company's newest technology and talks about how Nobilis will achieve critical mass. Recent news from Inovio Pharmaceuticals Inc. Biotech and medtech startups are not confined to the U. Unmet medical needs exist all over the globe, and they create a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship.
Healthcare Analyst Dennis Hulme of Edison Investment Research is headquartered in Sydney, and in this interview with The Life Sciences Report , he cites a group of Australian medtech and biotech names that investors should look at very carefully.
Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report , as well as a robust pipeline of generic options for a variety of indications.
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. In this interview with The Life Sciences Report , Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy CTE , a neurodegenerative disorder often found in professional football players through postmortem autopsy. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals. The company has several active clinical programs, led by bertilimumab, a first-in-class, fully human IgG4 monoclonal antibody, which is currently in Phase 2 clinical trials for the treatment of inflammatory bowel disease and skin disorders.
Immune Pharma also has a growing presence in immuno-oncology, with the goal to create a fully sustained oncology subsidiary in the near future. In this article for The Life Sciences Report, analyst Jason Napodano digs into the company's pipeline and investment potential. ROTH Capital Partners' Joseph Pantginis falls into that old-fashioned category of analysts who believe that good data can't help but drive a stock, no matter how far into the depths it may have sunk. In this interview with The Life Sciences Report , Pantginis presents his detailed growth theory on two names, and he leaves two Focus Picks on the table for investors to do further diligence on.
With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc. Christopher Schaber, holds an optimistic view of the company's future. Schaber expands on the status of the company's portfolio. Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to address that target and extend the lives of thousands of men.
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. In this interview with The Life Sciences Report , Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace. While the vagaries of the political season create uncertainty in the biotech and pharmaceutical sectors, companies are moving ahead with innovative cell therapies, gene therapies and new, safer ways to deliver addictive drugs, and investors find themselves in a position to play the development ideas with varying degrees of risk.
In this interview with The Life Sciences Report , George Zavoico of Jones Trading Institutional Services explores how the presidential race could affect the biotech industry, and explains the growth prospects of three biotech names that could strike gold. Data can create or destroy the value of a biotech investment in an instant, but hitting or missing an endpoint doesn't always tell the story. It took patience, time, additional capital and careful analysis of subpopulations of breast cancer patients to figure out that Herceptin would ultimately save many lives.
In this interview with The Life Sciences Report , George Zavoico of JonesTrading Institutional Services discusses the growth prospects of three biotech names that have been wrecked and left for dead, but could ultimately resurrect themselves from a misleading pile of rubble. Frank Oakes, the chairman, president and CEO of Stellar Biotechnologies, has a passion for the potential life-saving cures the ocean may provide. His company, a world leader in the production of sustainable, scalable and fully traceable GMP-grade KLH protein, has established research and manufacturing facilities along the Pacific Ocean to produce KLH, and Oakes himself has more than three decades of management experience in aquaculture.
In this interview with The Life Sciences Report , Oakes talks about how he got involved in this exciting and emerging space, and describes the potential Stellar KLH has in the burgeoning field of immunotherapy. It takes extraordinary dexterity to execute a strategic merger, and then to take first steps toward positioning a new molecular entity for a Phase 3 drug trial and potential partnership with a big pharma.
That's exactly the inflection point at which Diffusion Pharmaceuticals Inc. In this interview with The Life Sciences Report , Kalergis lays out Diffusion's plan for pivotal development of its treatment for primary brain cancer, which could drive the company's market cap to valuations that would bring huge upside to investors if successful. Lisa Crossley, describes the company's comprehensive hardware and software solution, dubbed CareKit, which allows patients to receive high-quality care in the home, improving health outcomes and enhancing quality of life for patients and families while reducing the cost of care.
According to newsletter writer Chen Lin, this is a huge binary event for the company. In this article, Lin lays out his investment thesis on the stock ahead of the meeting, and his hopes for eteplirsen's approval. Nobilis scans the market for clinics that can be acquired and scaled up using sophisticated direct marketing approaches. In this interview with The Life Sciences Report , Nobilis' mergers-and-acquisitions specialist Kolin Ozonian talks about the business model and tells investors how he and the Nobilis team plan to aggressively grow the company.
OTCMKTS , a small-cap biotech company focused on developing novel compounds for a range of applications, has released a flurry of announcements over the past five weeks as several of its pipeline drugs cleared regulatory hurdles and readied for their next milestones.
After a devastating start to , biotech stocks have snapped back. In the meantime, Molloy says, individual and small institutional investors can still buy growth stories at bargain prices. In this interview with The Life Sciences Report , Molloy mentions three names with near-term catalysts that, with good data, can bring a needed lift to biotech portfolios.
The Life Sciences Report's Small-Cap Biotech Watchlist was not immune to that movement, heading into negative territory almost from the moment the selected companies were introduced.
But as the market has shown signs of rebounding, so too has the Watchlist. Eden Rahim of Toronto-based Next Edge Capital has had his share of multibagger and grand-slam successes, and is one of the few mutual fund managers who feels comfortable investing in micro-cap biotech names side-by-side with billion-dollar biotech stocks.
In this interview with The Life Sciences Report , Rahim describes a group of micro-, small- and mid-cap biotech names possessing powerful growth drivers that could perform even when the overall market is not so hot.
Continuing stock market volatility is causing some investors to rethink their biotech investments. For generalists, in particular, choosing a winning company is almost a roll of the dice. Stock analysts fall into a few different categories.
There are buyside analysts and sellside analysts, and then there are independent analysts commissioned by companies to highlight underexposed business models and growth prospects. The independent analyst, such as Van Leeuwenhoeck's Marcel Wijma, normally works in the small- and micro-cap stock universe, where the buyside and sellside rarely go. In this interview with The Life Sciences Report , Wijma brings to light five diverse, overlooked small-cap biotech stocks from Canada, Europe and Australia that could bring huge returns to investor portfolios.
Patients on dialysis and cancer patients with indwelling catheters live with the possibility of contracting drug-resistant infections that can become more life threatening than their primary diseases.
MKT is developing a platform that has shown impressive results in preventing serious bloodstream infections. Chief Scientific Officer and Cofounder Antony Pfaffle, an internist who practiced nephrology, joins the conversation to relate his experience managing chronically ill patients undergoing catheter-based therapies in the critical care setting.
It takes nerves of steel to follow micro-cap stocks and ascribe future valuations in hefty multiples. In this interview with The Life Sciences Report , Selvaraju, a former big pharma researcher, details four growth names that could follow in the hallowed footsteps of previous winners.
Cynata Therapeutics of Australia has carved a technological niche in the fast-advancing cell therapy market with a platform that renders the production of stem cell-based treatments for cancer and diseases of the immune system easy and affordable, saving lives and money. In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver.
Canada is a wellspring for natural resources and the industries built around them. But the country also encompasses healthcare-related businesses that are growing, generating cash flow and flourishing. As a hedge fund and mutual fund manager concentrating on Canadian companies, he has made a specialty in acquisitions of cash-generating healthcare companies. In this interview with The Life Sciences Report , Campbell discusses seven small-cap growth names, all of which have reached share-price levels that do not reflect their capacity to grow.
Some may offer rare opportunities to buy at risk-mitigated value prices. Drug development seems to move at a snail's pace, but Cellceutix Corp. Ehrlich and Chief Medical Officer Dr. Daniel Jorgensen, an infectious disease specialist, discuss the candidates, beginning with the first new class of antibiotics to enter Phase 3 in skin infections in decades. Sometimes wonderful ideas live on and create value for the ages. This may prove a challenging year for small-cap biotechs, but the five analysts who selected companies for inclusion on The Life Sciences Report's Small-Cap Biotech Watchlist believe these companies have a good shot at producing innovative products in a variety of indications and producing value for investors.
Discovery, it turns out, is not just about finding the cure for a particular disease; it's also about finding the companies best poised to reach that goal. Combining academic discipline with methodical due diligence, Alan Leong of BioWatch News undertakes a regimented review of each biotech and medtech stock he investigates.
In some cases he will follow a company's clinical development program and data for years before he pulls the trigger and recommends a name. In this interview with The Life Sciences Report , Leong presents a number of names for investors' consideration. Many won't be mentioned in his usual write-ups: It's an early look at what's on his watch list and in his inbox. Each company carries its own risks, but every stock has a special growth story that could propel huge gains if data fall into place.
The new year is off to a turbulent start, with indices across all markets, including biotech, sliding downward in the face of headwinds from China. Canadian healthcare stocks offer a windbreak for biotech investors, however, especially if they select a diversified basket across the various sectors. There is no cure for ALS, a debilitating and ultimately fatal neurological disease. BrainStorm made the credibility-building announcement on the opening day of major biotech conferences in San Francisco.
Targeting diseases from inside the cell could be medicine's version of the dawn of the Internet. Or, as newsletter writer Chen Lin describes it, advances from companies like Sorrento Therapeutics Inc. The traditional biotech investor wants to hit the lottery with a blockbuster molecule, but there are less risky avenues to profit, where capital is deployed to leverage the healthcare market via reimbursement from Medicare, the Affordable Care Act and private-pay insurance. In this interview with The Life Sciences Report , Russell Stanley of Mackie Research Capital tells investors that growth is where you find it, including in acquisitions.
NASDAQ , is pioneering the potential use of an exosome-based biomarker to diagnose chronic traumatic encephalopathy CTE , a condition that otherwise can only be identified postmortem. As James "Jim" Joyce, executive chairman, tells The Life Sciences Report , other companies are exploring this approach in oncology, but Exosome Sciences is the only company advancing an exosome-based candidate to diagnose CTE.
The merger of RestorGenex Corp. The combined company will be named Diffusion Pharmaceuticals Inc. Before starting his own firm in July, Jason Napodano spent more than 12 years at Zacks Investment Research producing highly detailed small-cap biotechnology research. Today, as owner and senior analyst at BioNap Consulting, Napodano is doing much the same, but with more flexibility. He follows dozens of companies and continues to perform diligence on new names with the single goal of finding multibaggers.
One of his themes is to take a biotech basket-of-stocks approach, since he knows some names will fail but the winners will move upward with momentum.
In this interview with The Life Sciences Report , Napodano discusses small-cap names with the potential to power portfolios to extraordinary levels. In this interview with The Life Sciences Report , Gengos discusses his firm's recently reported Phase 2 data in glioblastoma, as well as the company's strategy for the upcoming registration trial.
In advance of the Biotech Showcase , The Life Sciences Report has once again solicited top analysts to provide the names of innovative biotech companies that investors should keep an eye on in the upcoming year. Why have stem cell and regenerative medicine companies underperformed other segments of biotech?
Maxim Group's Jason Kolbert and Dr. Jason McCarthy identify a possible answer: Investors believe stem cell data has yet to definitively reach proof of concept in the blockbuster indications that the companies are pursuing. In this interview with The Life Sciences Report , Kolbert and McCarthy tackle the issues that have frustrated investors, and leave readers with a list of names that could reap multiples on investment while patients enjoy longer lives.
This fall, presidential candidate Hillary Clinton once again proposed price caps on out-of-pocket payments for pharmaceuticals. Liana Moussatos of Wedbush Securities has followed the price-cap discussion since the s, and says the issue is more political than real.
Given that, she tells The Life Sciences Report about some up-and-coming companies with products she believes are likely to make big improvements in the health of patients and the wallets of investors. Several controversies have taken the air out of drug and biotech stocks, which performed quite well until midsummer. Among the injured players are generic drug makers, which landed hard after a high-flying period.
In this interview with The Life Sciences Report , the analyst identifies a handful of select generic drug and specialty pharma stocks that still have pricing power and margin expansion potential. Interventional radiology has been described as the surgery of the new millennium by Stanford Healthcare, offering less invasive procedures, more precise placement of catheters and, often, fewer complications for patients and higher throughput for healthcare facilities.
Robotics is making this new area of medicine possible. In this interview with The Life Sciences Report , Dushyanth focuses on four small- and micro-cap specialty pharma and device names with engineering tie-ins, and she expects all to produce exciting results for investors. Reni Benjamin of Raymond James has watched biotechnology move into a new era in which cells and genes can be manipulated to produce true disease-modifying results. In this interview with The Life Sciences Report , Benjamin outlines the groundbreaking work being done by a number of companies with the potential to return multiples on investment over the next two to three years.
Skin disorders encompass a broad class of medical indications, from psoriasis to melanoma. Many companies focus on developing treatments for specific dermatological indications, but few have been able to build product portfolios with the range of therapeutic and consumer products currently marketed by Cipher Pharmaceuticals. SeeThruEquity's Ajay Tandon and Jay Albany are riding the biotech bull by harnessing the huge upside potential of micro-cap companies working in multiple subsectors, particularly in the rapidly advancing cancer immunotherapy sector.
In this interview with The Life Sciences Report, Tandon and Albany toss the names of several companies into the arena for investors' consideration. Now this broad-spectrum platform is being tested against cancer and other life-threatening diseases. A strategy of over-the-counter sales helps derisk Nutra Pharma Corp.
Chronic inflammation causes long-term pain and tissue scarring, manifesting in a range of diseases from rheumatoid arthritis to liver cirrhosis. With the introduction of gene therapy and immunotherapeutics, novel strategies targeting inflammatory disorders are being developed, creating hope for patients with no other clinical options. Recent stock market volatility is an opportunity for biotech investors to pick up great stocks before market caps rise substantially.
Stem cell therapies have been slowed by high production costs, batch-to-batch variability and limited seed material. Ross Macdonald, CEO of Cynata Therapeutics, tells The Life Sciences Report how his company's innovative manufacturing methods can generate robust, consistent and inexpensive stem cells, and how this technology is likely to accelerate the commercialization of stem cell therapies worldwide.
In a volatile macroeconomic world, micro caps can offer some immunity as they move based on company news rather than front page headlines. But you have to pick your companies carefully. Regenerative medicine through stem cell technology is a source of hope for many suffering from ailments including Alzheimer's disease, diabetes, spinal cord injury and cancer.
While new therapeutic options are continually in development, progress has, until recently, been hampered by political and medical ethics arguments. Because of patient advocacy, new technologies are now advancing, from development of an artificial pancreas to the hope of culturing intact human organs. In this interview with The Life Sciences Report , Bernie Siegel, founder and executive director of the Genetics Policy Institute, describes recent progress and developments in the regenerative medicine universe.
Growth in company valuations has outpaced sales for several years, but the coming weeks will see rapid fluctuations as the two begin to realign. In this interview, Singh shares his predictions for the rest of with The Life Sciences Report , and identifies several companies to hold for potentially big returns. Immuno-oncology has the potential to not only transform medicine, but also to become a multibillion-dollar market for a drug developer with the right team and the right compound.
Maxim Group Equity Analyst Jason McCarthy has developed a biotechnology theme that leverages immunotherapy platforms serving both cancer and infectious disease indications. It's an elegant dual premise that enables one side to fund development of the other, and it seems to be working beautifully for companies and their shareholders. In this interview with The Life Sciences Report , McCarthy explains the principle and describes five companies proving up the model's profitability.
It's all about data for John McCamant and Jay Silverman of the Medical Technology Stock Letter , and right now it's festival time as we approach the busy season of market-moving catalysts and milestones.
From now until December, biotech investors will be focused on the press releases, webinars and scientific presentations that serve as a vitality tonic for the entire biotech industry. In this interview with The Life Sciences Report , McCamant and Silverman give a detailed picture of their growth theories on six biotech stocks that could reap many multiples on invested capital over the next few years.
With the markets in whiplash mode, Joe McAlinden, founder of McAlinden Research Partners and former chief global strategist with Morgan Stanley Investment Management, believes volatility is going to stick around for a while. In fact, he just announced that we might see a correction double of what we've had so far.
In this interview with Streetwise Reports , McAlinden bucks conventional wisdom and lays out his investing strategy for this period of market uncertainty. The growing need for recombinant proteins for vaccines and therapeutics is causing the biotech industry to look beyond vat fermentation and cell cultures for protein expression systems that, like iBio Inc. Bob Erwin describes the iBioLaunch technology and what it offers to drug developers and investors. CAR T-cell therapies show amazing potential in treating blood cancers, but there's a lot of work to do before the cells are ready for commercialization.
He also describes the reality behind the growing excitement in regenerative medicine, and what investors should know about some very innovative, but often overlooked, small companies. Ran Nussbaum, managing partner with The Pontifax Group, doesn't worry too much about overall market volatility. Biotechs, he feels, are somewhat immune to turmoil because their fundamentals are based in real life.
He prefers to play on good science and unmet medical needs, and then sit tight until a stock is discovered. In this interview with The Life Sciences Report , Nussbaum describes a few takeover candidates primed for stellar growth, as well as promising names that are part of the movement toward personalized medicine. The evidence is mounting: In the past five years, development of new therapies has aimed for true disease modification and actual cures.
Many novel ideas are now in the clinic, and have opened up fresh opportunities for dramatic industry growth, especially in the gene and cellular therapy realm. In this interview with The Life Sciences Report , David Nierengarten of Wedbush Securities brings a handful of select names to investors' attention, including a couple of companies with technologies that could revolutionize medicine.
Small-cap life science investors in the U. In Canada the focus is a bit different. Bruce Campbell of StoneCastle Investment Management has made a killing over the past year on rather unadventurous healthcare companies that have been acquiring smaller businesses and growing outward by fixing spokes to a hub. In this interview with The Life Sciences Report , Campbell describes five small-cap growth stories poised to ring up more acquisitions, more cash flow and more share price appreciation to portfolios.
Volatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That's the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies Capital. Can you grow a portfolio if some of your more successful names are called away by option buyers before the stock goes into the stratosphere?
The answer is yes, and in this interview with The Life Sciences Report , Rahim describes his technique and leaves readers with six names that he fully expects to reap very large gains. Regenerative medicine is surging toward the mainstream, and Athersys Inc.
Potential safety concerns surrounding cell therapies have been largely addressed, and now the efficacy of the company's MultiStem platform in several massive markets, including stroke, heart attack and acute pulmonary disease, are ready to be tested.
Regenerative medicine is just beginning to be understood by governments and investors alike. Last autumn, new regulations took effect in Japan that promise to speed patient access to some of these new therapies.
Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies developing stem cell and drug-device delivery systems that address complex disease indications ranging from blindness to spinal paralysis. Caroline Corner of Cantor Fitzgerald follows companies with technologies that can both address dire diseases and reap windfalls for investors.
In this interview with The Life Sciences Report , Corner brings important names to investors' attention. Investors who lament missing the U. Biotech valuations in Australia are not in sync with U. Direct-acting antiviral therapies are poised to become a major disruptive technology in treatment for viruses, including human rhinovirus and human papillomavirus. Revenue and earnings at the big biotechs are signaling investors that the market is still strong, and that there is still a huge thirst for early-stage devices, small molecules, biologics and cellular therapies.
In this interview with The Life Sciences Report , Napodano details the upside for small-cap biotech names that he believes will be huge gainers for investor portfolios. The life sciences industry is evolving rapidly. Many say it's at the beginning of an explosive growth stage that will see the development and commercialization of novel therapeutics and diagnostics still being imagined in scientific laboratories today.
This explosion of innovation also means an explosion of investment opportunity.
Category Archives: Weed Knowledge
elimination half-life of THC is about 7 days, and complete elimination of a single dose .. Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological .. directly related to the degree of anaplasia and grade of tumor. Cannabinoids and their derivatives have been used for years in folk. A cannabis health and education center for anyone interested in medical marijuana. And through this less restrictive concept, allow them to live a healthier The folks behind marijuana-based rehab understand its importance more than most. guide for understanding the differences between hemp- derived CBD oils. WBC Champion boxer, cannabis advocate, and friend of Dixie, Ava Knight, are dedicated to living healthy and active lifestyles with cannabis and hemp. . Now that the laws have changed, Hancock believes that it's unjust to still . Get your dose of nutritious hemp seed oil while you're at work, at home or.